Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-04-09 | Gregg A. Lapointe, CPA, MBA, age 60, joined us as director in November 2017. ... The following three directors are the current members of the Audit Committee: Mr. Goodwin, Mr. Katkin and Mr. Lapointe. ... The following three directors are the members of the Corporate Governance, Health Care Compliance Oversight and Nominating Committee: Mr. Lapointe, Dr. Ringrose, and Dr. Kotzin. ... Mr. Lapointe was appointed to, and made chairman of, the Corporate Governance, Health Care Compliance Oversight and Nominating Committee on February 1, 2018. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2018: Gregg A. Lapointe 73,250 fees earned in cash, 77,748 option awards, total 150,998. |
| 2022-04-05 | Gregg A. Lapointe, CPA, MBA, age 63, joined us as director in November 2017. Mr. Lapointe is currently the chief executive officer and co-founder of Cerium Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing medicines for patients with rare diseases. ... The Board concluded that Mr. Lapointe should continue to serve as a member of the Board in part due to his significant experience in the areas of global strategic planning and implementation, business development, corporate finance, and acquisitions, and his experience as an executive officer and board member in the pharmaceutical and medical products industries. |
| 2023-04-14 | Gregg A. Lapointe, CPA, MBA, age 64, joined us as a director in November 2017. ... Mr. Lapointe is currently the Chairman of the Board. ... The following directors are currently members of the Audit Committee: Mr. Lapointe serves as Chair. ... The following directors are currently members of the Compensation Committee: Mr. Lapointe ... The following directors currently serve on the Finance Committee: Mr. Lapointe. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2022: Gregg A. Lapointe Fees Earned or Paid in Cash ($) 108,538 Stock Awards ($) 50,250 Option Awards ($) 40,926 Total ($) 199,714. |
| Filing Date | Source Excerpt |
|---|---|
| 2019-07-26 | Gregg A. Lapointe, CPA, MBA has been a director since March 2009. Our Board of Directors has an Audit Committee, which is comprised of Mr. Brownlie (Chair), Mr. Lapointe and Dr. Rubin. After the Annual Meeting, the Audit Committee will be comprised of Mr. Lapointe (Chair), Mr. Pearson and Dr. Rubin. Our Board of Directors has a Nominating and Corporate Governance Committee, which is comprised of Dr. Zeldis (Chair), Mr. Brownlie and Mr. Lapointe. After the Annual Meeting, the Nominating Committee will be comprised of Dr. Zeldis (Chair), Mr. Lapointe and Ms. Parks. The following table contains information concerning the compensation of the non-employee directors during the year ended December 31, 2018. Gregg A. Lapointe: Fees Earned Paid in Cash: $47,500, Option Awards: $30,000, Total: $77,500. |
| 2020-08-07 | Gregg A. Lapointe, CPA, MBA has been a director since March 2009. Mr. Lapointe is currently CEO of Cerium Pharmaceuticals, Inc. and serves on the Board of Directors of Rigel Pharmaceuticals, Inc., Cytori Therapeutics, Inc. and Catabasis Pharmaceuticals, Inc. ... Our Board of Directors has an Audit Committee, which is comprised of Mr. Lapointe (Chair), Ms. Parks and Dr. Rubin. ... Our Board of Directors has a Compensation Committee, which is comprised of Dr. Rubin (Chair), Mr. Lapointe and Dr. Zeldis. ... Our Board of Directors has a Nominating and Corporate Governance Committee ("Nominating Committee"), which is comprised of Dr. Zeldis (Chair), Mr. Lapointe and Ms. Parks. |
| 2021-08-10 | Gregg A. Lapointe, CPA, MBA has been a director since March 2009. Mr. Lapointe is currently CEO of Cerium Pharmaceuticals, Inc. and serves on the Board of Directors of Rigel Pharmaceuticals, Inc. and Catabasis Pharmaceuticals, Inc. ... Our Board of Directors has an Audit Committee, which is comprised of Mr. Lapointe (Chair), Ms. Parks and Dr. Rubin. ... Our Board of Directors has a Compensation Committee, which is comprised of Dr. Rubin (Chair), Mr. Lapointe and Dr. Zeldis. ... Our Board of Directors has a Nominating and Corporate Governance Committee ("Nominating Committee"), which is comprised of Dr. Zeldis (Chair), Mr. Lapointe and Ms. Parks. ... Compensation of Directors table shows Gregg A. Lapointe earned $58,750 in cash and $30,000 in option awards for a total of $88,750 in 2020. |
| 2022-08-05 | Gregg A. Lapointe, CPA, MBA has been a director since March 2009. Mr. Lapointe is currently CEO of Cerium Pharmaceuticals, Inc. and serves on the Board of Directors of Rigel Pharmaceuticals, Inc. Astria Therapeutics, Inc. Mr. Lapointe has previously served on the Board of Directors of Plus Therapeutics, Inc. (formerly known as Cytori Therapeutics, Inc.), ImmunoCellular Therapeutics Ltd., Raptor Pharmaceuticals, Inc., SciClone Pharmaceuticals, Inc., the Pharmaceuticals Research and Manufacturers of America (PhRMA), Questcor Pharmaceuticals, Inc. and the Board of Trustees of the Keck Graduate Institute of Applied Life Sciences. He previously served in varying roles for Sigma-Tau Pharmaceuticals, Inc. (now known as Leadiant Biosciences, Inc.), a private biopharmaceutical company, from September 2001 through February 2012, including Chief Operating Officer from November 2003 to April 2008 and Chief Executive Officer from April 2008 to February 2012. From May 1996 to August 2001, he served as Vice President of Operations and Vice President, Controller of AstenJohnson, Inc. (formerly JWI Inc.). Prior to that, Mr. Lapointe spent several years in the Canadian medical products industry in both distribution and manufacturing. Mr. Lapointe began his career at Price Waterhouse. Mr. Lapointe received his B.A. degree in Commerce from Concordia University in Montreal, Canada, a graduate diploma in Accountancy from McGill University and his M.B.A. degree from Duke University. |
| 2023-08-07 | Mr. Lapointe received his B.A. degree in Commerce from Concordia University in Montreal, Canada, a graduate diploma in Accountancy from McGill University and his M.B.A. degree from Duke University. |
| 2024-04-29 | Gregg A. Lapointe, CPA, MBA has been a director since March 2009. Mr. Lapointe is currently CEO of Cerium Pharmaceuticals, Inc. and serves on the board of directors of Rigel Pharmaceuticals, Inc., and Astria Therapeutics, Inc. as well as other private biopharma companies. The Audit Committee includes Gregg A. Lapointe, CPA (Chair). The Nominating and Corporate Governance Committee includes Mr. Lapointe. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22